Bio Path Holdings Inc (BPTH)

[Snug9]

Blairsoldman, the simple answer to your question is that the term “salvage patient” as used in a clinical study protocol allows patients on whom the traditional treatments have not worked to be used as guinea pigs for the clinical trial. Even if the test proves to be successful during the trial for a specific indication, in the case of BP-1001 AML, the treatment cannot be generally used until FDA approval is given for the treatment for the specific indication tested. That is what we are all “patiently” waiting for right now for BP-1001!
If BioPath were to allow BP-1001 to be used by anyone outside of the approved clinical trial sites the FDA has the authority to shut them down.